Wedbush Reiterates Neutral on Cogent Biosciences, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated a Neutral rating on Cogent Biosciences (NASDAQ:COGT) and maintained a $10 price target.
May 24, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst David Nierengarten has reiterated a Neutral rating on Cogent Biosciences and maintained a $10 price target.
The reiteration of a Neutral rating and maintenance of the $10 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100